These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 28669337)

  • 1. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
    Gupta A; Ahmad A; Dar AI; Khan R
    Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
    Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
    Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Nanotechnology from Bench to Bedside.
    Sapalidis K; Kosmidis C; Laskou S; Katsaounis A; Mantalobas S; Passos I; Michalopoulos N; Amaniti A; Sardeli C; Zarogoulidis P
    Curr Cancer Drug Targets; 2019; 19(1):3-4. PubMed ID: 30672409
    [No Abstract]   [Full Text] [Related]  

  • 4. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.
    Jang SF; Liu WH; Song WS; Chiang KL; Ma HI; Kao CL; Chen MT
    Int J Mol Sci; 2014 Mar; 15(3):3904-25. PubMed ID: 24599081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology and nanomedicine: going small means aiming big.
    Teli MK; Mutalik S; Rajanikant GK
    Curr Pharm Des; 2010 Jun; 16(16):1882-92. PubMed ID: 20222866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy?
    Kateb B; Chiu K; Black KL; Yamamoto V; Khalsa B; Ljubimova JY; Ding H; Patil R; Portilla-Arias JA; Modo M; Moore DF; Farahani K; Okun MS; Prakash N; Neman J; Ahdoot D; Grundfest W; Nikzad S; Heiss JD
    Neuroimage; 2011 Jan; 54 Suppl 1(Suppl 1):S106-24. PubMed ID: 20149882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lethality on drug discovery: an update on cancer therapy.
    Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
    Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Double Strand Break Repair - Related Synthetic Lethality.
    Toma M; Skorski T; Sliwinski T
    Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.
    Merajver S; Phadke S; Soellner M
    Trans Am Clin Climatol Assoc; 2017; 128():169-179. PubMed ID: 28790501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
    Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
    Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic lethal vulnerabilities of cancer.
    Fece de la Cruz F; Gapp BV; Nijman SM
    Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
    Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
    Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine.
    Adir O; Poley M; Chen G; Froim S; Krinsky N; Shklover J; Shainsky-Roitman J; Lammers T; Schroeder A
    Adv Mater; 2020 Apr; 32(13):e1901989. PubMed ID: 31286573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology.
    Hauert S; Bhatia SN
    Trends Biotechnol; 2014 Sep; 32(9):448-55. PubMed ID: 25086728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic lethality: a step forward for personalized medicine in cancer.
    Jariyal H; Weinberg F; Achreja A; Nagarath D; Srivastava A
    Drug Discov Today; 2020 Feb; 25(2):305-320. PubMed ID: 31811941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision gas therapy using intelligent nanomedicine.
    He Q
    Biomater Sci; 2017 Oct; 5(11):2226-2230. PubMed ID: 28937694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora kinase A, a synthetic lethal target for precision cancer medicine.
    Mou PK; Yang EJ; Shi C; Ren G; Tao S; Shim JS
    Exp Mol Med; 2021 May; 53(5):835-847. PubMed ID: 34050264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethality: emerging targets and opportunities in melanoma.
    Thompson N; Adams DJ; Ranzani M
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):183-193. PubMed ID: 28097822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.